BRPI1008705A2 - variantes de aglutinação de anti-soro albumina aperfeiçoadas - Google Patents

variantes de aglutinação de anti-soro albumina aperfeiçoadas

Info

Publication number
BRPI1008705A2
BRPI1008705A2 BRPI1008705A BRPI1008705A BRPI1008705A2 BR PI1008705 A2 BRPI1008705 A2 BR PI1008705A2 BR PI1008705 A BRPI1008705 A BR PI1008705A BR PI1008705 A BRPI1008705 A BR PI1008705A BR PI1008705 A2 BRPI1008705 A2 BR PI1008705A2
Authority
BR
Brazil
Prior art keywords
variants improved
agglutination
albumin antiserum
albumin
antiserum agglutination
Prior art date
Application number
BRPI1008705A
Other languages
English (en)
Inventor
Carolyn Enever
Elena De Angelis
Haiqun Liu
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1008705A2 publication Critical patent/BRPI1008705A2/pt
Publication of BRPI1008705B1 publication Critical patent/BRPI1008705B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1008705-2A 2009-02-19 2010-02-17 Domínio variável único da imunoglobulina anti-soro albumina, ligante multiespecífico compreendendo o dito domínio, proteína de fusão fundida ao dito domínio, composição, ácido nucleico e vetor compreendendo o dito ácido nucleico BRPI1008705B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US61/153.746 2009-02-19
US16399009P 2009-03-27 2009-03-27
US61/163.990 2009-03-27
PCT/EP2010/052007 WO2010094722A2 (en) 2009-02-19 2010-02-17 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
BRPI1008705A2 true BRPI1008705A2 (pt) 2016-03-08
BRPI1008705B1 BRPI1008705B1 (pt) 2021-05-25

Family

ID=42306619

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008705-2A BRPI1008705B1 (pt) 2009-02-19 2010-02-17 Domínio variável único da imunoglobulina anti-soro albumina, ligante multiespecífico compreendendo o dito domínio, proteína de fusão fundida ao dito domínio, composição, ácido nucleico e vetor compreendendo o dito ácido nucleico

Country Status (23)

Country Link
US (2) US9175071B2 (pt)
EP (1) EP2398825B1 (pt)
JP (1) JP5766616B2 (pt)
KR (1) KR101820968B1 (pt)
CN (2) CN105061593B (pt)
AR (1) AR075506A1 (pt)
AU (2) AU2010215481C1 (pt)
BR (1) BRPI1008705B1 (pt)
CA (1) CA2753130C (pt)
CL (1) CL2011002023A1 (pt)
CO (1) CO6450689A2 (pt)
DO (1) DOP2011000269A (pt)
EA (1) EA027866B1 (pt)
ES (1) ES2654929T3 (pt)
IL (1) IL214481A0 (pt)
MA (1) MA33052B1 (pt)
MX (1) MX2011008752A (pt)
PE (1) PE20120170A1 (pt)
SG (1) SG173488A1 (pt)
TW (1) TW201042041A (pt)
UY (1) UY32452A (pt)
WO (1) WO2010094722A2 (pt)
ZA (1) ZA201105658B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
AR075505A1 (es) 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
US8779103B2 (en) * 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
SG185437A1 (en) * 2010-05-20 2012-12-28 Glaxo Group Ltd Improved anti-serum albumin binding variants
EP2603522A1 (en) 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
BR112013007442A2 (pt) * 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
PT3583125T (pt) 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Proteínas de fusão ao domínio de ligação à albumina
CN110709418B (zh) * 2017-06-05 2023-09-26 努玛治疗有限公司 新型抗hsa抗体
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS
KR102204315B1 (ko) * 2018-11-16 2021-01-18 한국세라믹기술원 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도
WO2022125566A1 (en) * 2020-12-08 2022-06-16 Janux Therapeutics, Inc. Half-life extending compositions and methods
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
TW202608919A (zh) * 2024-04-12 2026-03-01 美商派拉岡醫療公司 白蛋白結合蛋白及使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713272A1 (de) 1997-03-29 1998-10-08 Junghans Uhren Gmbh Zeitzonen-Uhr
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
CA2589802A1 (en) 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CA2688434A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2744588A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13

Also Published As

Publication number Publication date
AU2010215481A1 (en) 2011-08-25
AU2014202764B2 (en) 2016-07-07
JP2012517819A (ja) 2012-08-09
DOP2011000269A (es) 2011-12-31
EA201171067A1 (ru) 2012-02-28
AU2014202764A1 (en) 2014-06-12
CA2753130A1 (en) 2010-08-26
US20160075774A1 (en) 2016-03-17
CL2011002023A1 (es) 2012-04-09
KR101820968B1 (ko) 2018-01-23
AR075506A1 (es) 2011-04-06
PE20120170A1 (es) 2012-03-21
TW201042041A (en) 2010-12-01
BRPI1008705B1 (pt) 2021-05-25
CN102405232B (zh) 2015-08-19
UY32452A (es) 2010-09-30
ES2654929T3 (es) 2018-02-15
CN105061593A (zh) 2015-11-18
KR20110127224A (ko) 2011-11-24
MA33052B1 (fr) 2012-02-01
CN105061593B (zh) 2018-08-03
IL214481A0 (en) 2011-09-27
US9751935B2 (en) 2017-09-05
MX2011008752A (es) 2011-09-06
US20110300158A1 (en) 2011-12-08
EP2398825A2 (en) 2011-12-28
CA2753130C (en) 2020-07-14
WO2010094722A3 (en) 2011-01-13
AU2010215481C1 (en) 2015-06-04
US9175071B2 (en) 2015-11-03
CN102405232A (zh) 2012-04-04
EP2398825B1 (en) 2017-10-25
EA027866B1 (ru) 2017-09-29
ZA201105658B (en) 2012-05-25
WO2010094722A2 (en) 2010-08-26
AU2010215481B2 (en) 2014-02-20
SG173488A1 (en) 2011-09-29
JP5766616B2 (ja) 2015-08-19
CO6450689A2 (es) 2012-05-31

Similar Documents

Publication Publication Date Title
FIC20250029I1 (fi) neratinibi
FIC20230025I1 (fi) neratinibi
EP2482848A4 (en) Endoglin antibodies
PT2406284T (pt) Anticorpos anti-bcma
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
SMT201400089B (it) Fermo sismico
ECSP12012034A (es) Antagonistas de pcsk9
EP2473531A4 (en) Anti-gitr antibodies
HUE056626T2 (hu) Antitestkészítmény
BR112012030311A2 (pt) anticorpo
PT2530091T (pt) Anticorpo anti-dll3
BRPI1008774A2 (pt) espiroamida substituída
EP2454985A4 (en) aperture stop
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
PL2404485T3 (pl) Automatyczne konfigurowanie oświetlenia
BR112013010687A2 (pt) combinações de anticorpos c-met
EP2629796A4 (en) ANTIBODY
BR112012003602A2 (pt) imunoensaio de imatinibe
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI1015957A2 (pt) Lanche impregnado de sabor de castanha
BRPI0912769A2 (pt) anticorpos anti-pirb
PL2474315T3 (pl) Induktor odpowiedzi immunologicznej
EP2448583A4 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
EP2448584A4 (en) Substituted 4-hydroxypropyl-5-carboxamide

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: GLAXO GROUP LIMITED (GB)